Veterinary Medicines

Biocan Novel DHPPi, Lyophilisate and solvent for suspension for injection

Authorised
  • Canine distemper virus, strain CDV Bio 11/A, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
  • Canine parainfluenza virus 2, strain CPiV-2-Bio 15, Live
Download as PDF

Product identification

Medicine name:
Biocan Novel DHPPi, Lyophilisate and solvent for suspension for injection
Biocan Novel DHPPi, süstesuspensiooni lüofilisaat ja lahusti koertele
Active substance:
  • Canine distemper virus, strain CDV Bio 11/A, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
  • Canine parainfluenza virus 2, strain CPiV-2-Bio 15, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain CDV Bio 11/A, Live
    5.10
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
    5.30
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine parvovirus 2b, strain CPV-2b Bio 12/B, Live
    6.60
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine parainfluenza virus 2, strain CPiV-2-Bio 15, Live
    5.10
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:
  • Glass Vial 50 x 1.0 Dose
  • Glass Vial 25 x 1.0 Dose
  • Glass Vial 10 x 1.0 Dose

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Bioveta a.s.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1856
Date of authorisation status change:
Reference member state:
  • Czechia
Procedure number:
  • CZ/V/0124/001
Concerned member states:
  • Bulgaria
  • Croatia
  • Cyprus
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Poland
  • Romania
  • Slovakia
  • Slovenia

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 3/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."